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Abstract 
The KRAS gene is frequently mutated in multiple cancer types, but it fell off the drug discovery radar for many years 
because of its inherent “undruggable” structure and undefined biological properties. As reported in the paper entitled 
“Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK” in Nature Com-
munications, we performed a synthetic lethal screening with a combinatorial strategy on a panel of clinical drugs; we 
found that combined inhibition of polo-like kinase 1 and RhoA/Rho kinase markedly suppressed tumor growth in 
mice. An increase in the expression of the tumor suppressor P21WAF1/CIP1 contributed to the synergistic mechanism of 
the combination therapy. These findings open a novel avenue for the treatment of KRAS-mutant lung cancer.
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Main text
RAS genes (KRAS, HRAS, and NRAS) act as guanosine 
triphosphate (GTP)/guanosine diphosphate (GDP)-reg-
ulated binary on–off switches, regulating diverse normal 
cellular functions. Reportedly, nearly one-third of human 
cancers exhibit aberrantly activated RAS mutations [1]. 
As a principal isoform of three RAS genes, KRAS is the 
“black sheep” in this family, and cancers related to muta-
tions in KRAS (KRAS4A and KRAS4B) alone account for 
approximately one million deaths per year [2]. Although 
intensive studies have been conducted on K-Ras protein 
structure, biochemistry, signaling, and biology, effec-
tive treatments for KRAS-mutant cancers have not yet 
been developed. Recent discovery of KRASG12C-selective 
inhibitors has invigorated the Ras community [3, 4]; how-
ever, these compounds are currently used as chemical 
probes to delineate K-Ras signaling rather than as thera-
peutic agents that can be translated directly to the clinic.
As an indirect approach to target mutant KRAS, syn-
thetic lethality studies have found a novel way to block 
mutant K-Ras signaling [5]. Several synthetic lethal RNA 
interference screening studies have characterized a list of 
synthetic lethal interactors of mutant KRAS [6–8]. Clini-
cal inhibitors targeting some of these synthetic lethal 
partners, such as the anti-apoptotic protein B cell lym-
phoma-extra large (BCL-XL), cyclin-dependent kinase 
4 (CDK4), and serine/threonine-protein kinase TBK1, 
have already been tested in clinical settings in a combi-
natorial strategy with a mitogen-activated protein kinase 
(MEK) inhibitor to treat KRAS-mutant cancers [5]. These 
important achievements based on synthetic lethality 
encouraged us to perform a chemical screening in the 
hope of developing efficacious clinical regimens to ben-
efit patients with KRAS-driven cancers. As reported in 
the paper entitled “Suppression of KRas-mutant cancer 
through the combined inhibition of KRAS with PLK1 
and ROCK” [9] in a recent issue of Nature Communica-
tions, we developed a synthetic lethal drug screening with 
a combinatorial strategy using a panel of clinical agents, 
and we identified several unique genotype-selective syn-
ergistic drug pairs that selectively killed KRAS-mutant 
cells but spared untransformed ones. In addition, we sys-
tematically investigated the selective anti-RAS efficacy of 
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the best combinatorial hit that inhibited both polo-like 
kinase 1 (PLK1) and RhoA/Rho kinase (ROCK).
In this study, we employed the primary screening in 
paired isogenic cell lines T29 and T29Kt1. Mutation-
ally activated KRASG12V was constitutively expressed in 
T29Kt1 cells, which could form subcutaneous tumors 
after being injected into immunocompromised mice [10]. 
According to the assumption that tumor initiation, pro-
gression, and heterogeneity are primarily driven by mul-
tiple genetic disorders rather than by a single defect, a 
“cocktail” of drugs is often given to achieve more potent 
efficacy [11]. Therefore, we employed a combinatorial 
strategy on a panel of clinical agents targeting K-Ras 
signaling directly or indirectly, including K-Ras upstream 
pathways, K-Ras downstream pathways, or mutant 
K-Ras-dependent pathways. By analyzing the combinato-
rial efficacy of over 300 pairs of different drug combina-
tions with a Fa-CI plot, we found that the unique drug 
pair of BI-2536 (a PLK1 inhibitor) and fasudil (a ROCK 
inhibitor) was among the most efficacious. Inhibition of 
KRAS-mutant tumors by using surrogate drugs already 
approved for clinical use results in the fastest translation 
to the clinic. In line with these findings, BI-2536 has been 
reported in phase II clinical trials to effectively inhibit dif-
ferent types of tumor [12], and fasudil has been approved 
in Japan and China for the treatment of cerebral vasos-
pasm, stroke, and hypertension, indicating that the com-
bination of these drugs has acceptable clinical toxicity 
and significant translational potential. Also, we used four 
untransformed cell lines and 28 cancer cell lines with 
different genotypes, including KRAS mutation, NRAS 
mutation, epidermal growth factor receptor (EGFR) 
mutation, and KRAS wild-type, to verify the synergis-
tic effect of the synthetic lethal genes polo-like kinase 1 
(PLK1) and RhoA/Rho kinase (ROCK). As expected, the 
selectivity and specificity of this combination toward 
KRAS-mutant cells were further revealed. Next, the Lox-
Stop-Lox (LSL)-KRASG12D mouse model and a patient-
derived tumor explant model of lung cancer carrying an 
activating KRASG12D mutation were set up to evaluate the 
in  vivo efficacy and toxicity of combining BI-2536 and 
fasudil. Mice were treated with clinically relevant doses 
of BI-2536 and fasudil by either intravenous injection or 
oral gavage, leading to a significant reduction of tumor 
growth and extended mouse survival. These results indi-
cate that our synthetic lethal screening study, based on 
clinically available drugs and drug combinations, may 
be help to develop potential novel and efficacious treat-
ments for recalcitrant KRAS-mutant lung cancer.
We used a microarray analysis and several cell func-
tion assays to define the potential targets of the combined 
inhibition of PLK1 and ROCK. The gene expression pro-
files in KRAS-mutant A549 cells treated with BI-2536 and 
fasudil showed that the p53 signaling pathway had the 
highest number of significantly up-regulated genes and 
was significantly involved in the sensitivity of this drug 
pair. To further examine the precise mechanism of action 
of this combination therapy, we detected the protein lev-
els of P53 and its several downstream targets. This com-
bination had little effect on P53 protein level; however, it 
acutely increased the level of the cyclin-dependent kinase 
(CDK) inhibitor P21WAF1/CIP1 in KRAS-mutant T29Kt1 
cells but not in the isogenic wild-type T29 cells. Simi-
lar mechanism results were obtained in several KRAS-
mutant lung cancer cell lines.
A large body of literature shows that the CDK inhibitor 
P21 functions as both a sensor and an effector of multi-
ple anti-proliferative signals [13]. P21 is implicated in cell 
mitotic regulation owing to its ability to stabilize CDK-
cyclin complexes; furthermore, it binds to and inhibits 
proliferative cell nuclear antigen through its carboxyl-
terminal domain. In addition, we confirmed the under-
lying mechanism of the combined inhibition of PLK1 
and ROCK using P21 total knockout cells generated by 
the CRISPR/CAS9 system. The results showed that total 
depletion of P21 led to a complete rescue of G2/M arrest 
mediated by the drug pair only in KRAS-mutant cancer 
cells, suggesting that P21 was unambiguously necessary 
for the combinatorial action. Because it has been sug-
gested that mutations in KRAS contribute to chromo-
some instability and mitotic stress [14], we assumed that 
increased mitotic stress by activating P21WAF1/CIP1 would 
cause susceptibility to apoptosis in KRAS-mutant cells. 
Such speculation is consistent with the perception of the 
“non-oncogene addiction” property of cancer cells. Col-
lectively, our mechanism study of the combined inhibi-
tion of PLK1 and ROCK revealed a new synthetic lethal 
interaction between KRAS and CDKN1A (encoding P21), 
as genetic or pharmacologic increase of P21WAF1/CIP1 level 
preferentially impairs the growth of KRAS-mutant cells.
Conclusions
Our study demonstrated the clinical feasibility of explor-
ing a synthetic lethal regimen of the combined inhibi-
tion of PLK1 and ROCK to defeat KRAS-mutant cancer 
through a mechanism that involves activation of tumor 
suppressor P21. CDKN1A is characterized as a new “syn-
thetic lethal partner” of mutant KRAS by overloading cell 
mitosis stress, especially in KRAS-mutant cells. Finally, 
we showed that this combinatorial strategy, by target-
ing the synthetic lethal partners of the oncogene KRAS, 
is a potential novel and efficacious treatment of KRAS-
mutant cancers. This combinatorial drug screening based 
on synthetic lethality may be similarly applied to other 
oncogenic drivers or tumor suppressors that have been 
generally thought to be “undruggable.”
Page 3 of 3Pang and Liu  Chin J Cancer  (2016) 35:92 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Authors’ contributions
XP drafted the manuscript, and ML revised the manuscript. Both authors read 
and approved the final manuscript.
Acknowledgements
We thank all members of Mingyao Liu’s laboratory for their collaborative work 
and critical thinking. We apologize for omitting, due to space limitations, the 
citations of some important studies.
Competing interests
The authors declare that they have no competing interests.
Funding
This study was supported by grants from the National Natural Science Foun-
dation of China (Grant 81672758), the Science and Technology Commission 
of Shanghai Municipality (Grants 16ZR1410400 and 14DZ2270100), and the 
Fundamental Research Funds for the Central Universities (Grant 78260029).
Received: 11 July 2016   Accepted: 15 September 2016
References
 1. Cox AD, Der CJ. Ras history: the saga continues. Small GTPases. 
2010;1(1):2–27. doi:10.4161/sgtp.1.1.12178.
 2. McCormick F. KRAS as a therapeutic target. Clin Cancer Res. 
2015;21(8):1797–801. doi:10.1158/1078-0432.CCR-14-2662.
 3. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibi-
tors allosterically control GTP affinity and effector interactions. Nature. 
2013;503(7477):548–51. doi:10.1038/nature12796.
 4. Lito P, Solomon M, Li LS, Hansen R, Rosen N. Allele-specific inhibitors 
inactivate mutant KRAS G12C by a trapping mechanism. Science. 
2016;351(6273):604–8. doi:10.1126/science.aad6204.
 5. Singh H, Longo DL, Chabner BA. Improving prospects for targeting RAS. J 
Clin Oncol. 2015;33(31):3650–9. doi:10.1200/JCO.2015.62.1052.
 6. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, et al. 
A genome-wide RNAi screen identifies multiple synthetic lethal interac-
tions with the Ras oncogene. Cell. 2009;137(5):835–48. doi:10.1016/j.
cell.2009.05.006.
 7. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. System-
atic RNA interference reveals that oncogenic KRAS-driven cancers require 
TBK1. Nature. 2009;462(7269):108–12. doi:10.1038/nature08460.
 8. Puyol M, Martin A, Dubus P, Mulero F, Pizcueta P, Khan G, et al. A syn-
thetic lethal interaction between K-Ras oncogenes and Cdk4 unveils 
a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell. 
2010;18(1):63–73. doi:10.1016/j.ccr.2010.05.025.
 9. Wang J, Hu K, Guo J, Cheng F, Lv J, Jiang W, et al. Suppression of KRas-
mutant cancer through the combined inhibition of KRAS with PLK1 and 
ROCK. Nat Commun. 2016. doi:10.1038/ncomms11363.
 10. Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, 
et al. A genetically defined model for human ovarian cancer. Cancer Res. 
2004;64(5):1655–63.
 11. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug 
resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714–26. 
doi:10.1038/nrc3599.
 12. Schoffski P, Blay JY, De Greve J, Brain E, Machiels JP, Soria JC, et al. Multi-
centric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in 
patients with advanced head and neck cancer, breast cancer, ovarian 
cancer, soft tissue sarcoma and melanoma. The first protocol of the 
European Organization for Research and Treatment of Cancer (EORTC) 
Network of Core Institutes (NOCI). Eur J Cancer. 2010;46(12):2206–15. 
doi:10.1016/j.ejca.2010.03.039.
 13. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. 
Nat Rev Cancer. 2009;9(6):400–14. doi:10.1038/nrc2657.
 14. De Raedt T, Walton Z, Yecies JL, Li D, Chen Y, Malone CF, et al. Exploit-
ing cancer cell vulnerabilities to develop a combination therapy 
for ras-driven tumors. Cancer Cell. 2011;20(3):400–13. doi:10.1016/j.
ccr.2011.08.014.
